CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine, a CD19-targeted therapy, received accelerated approval for treating adult patients with relapsed/refractory DLBCL, a decision influenced by the results of the phase II LOTIS-2 trial (88).